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Proteomics: in pursuit of effective traumatic brain injury 
therapeutics
Pavel N. Lizhnyak and Andrew K. Ottens*
Department of Anatomy and Neurobiology, Virginia Commonwealth University School of 
Medicine, Richmond, VA 23298, USA
Summary
Effective traumatic brain injury (TBI) therapeutics remain stubbornly elusive. Efforts in the field 
have been challenged by the heterogeneity of clinical TBI, with greater complexity among 
underlying molecular phenotypes than initially conceived. Future research must confront the 
multitude of factors comprising this heterogeneity, representing a big data challenge befitting the 
coming informatics age. Proteomics is poised to serve a central role in prescriptive therapeutic 
development, as it offers an efficient endpoint within which to assess post-TBI biochemistry. We 
examine rationale for multifactor TBI proteomic studies and the particular importance of temporal 
profiling in defining biochemical sequences and guiding therapeutic development. Lastly, we offer 
perspective on repurposing biofluid proteomics to develop theragnostic assays with which to 
prescribe, monitor and assess pharmaceutics for improved translation and outcome for TBI 
patients.
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Advancement in the therapeutic care of traumatic brain injury (TBI) has been slow to come, 
despite growing recognition of over 2 million incidents annually in the U.S. [1,2]. Drugs 
found effective in the laboratory have failed repeatedly in clinical trials [3–12]. Upon 
reflection, we have been ineffective in matching a drug’s pharmacology within the 
heterogeneous human TBI population [13]. TBI pathobiology varies in its evolution and 
complexity based on individualized injury-related, demographic and genetic factors [14,15]. 
Thus, a more targeted approach to TBI therapeutics is desired, one that translates an 
expanded understanding of a drug’s biochemical actions after injury into individualized 
therapy that provides the right compound to the right patient at the right time.
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Proteomics stands to influence how we select and evaluate drugs and develop objective 
theragnostic endpoints for more effective TBI treatment. Pharmaceutics often work by 
manipulating protein processes (e.g., enzyme inhibitors, receptor antagonists, etc.) 
responsible for a wide range of biological activities (e.g., synthesis, enzymatic/metabolic, 
scaffolding and morphologic, trafficking, cell-to-cell communication, etc). We discuss how 
proteomics allows us to delve deeper into the protein-mediated biochemistry underlying TBI 
and the subsequent action of candidate drugs when instrumenting non-targeted, large-scale 
mass spectrometric analysis in multifactor study designs. We examine how proteomics can 
inform on novel therapeutic windows of opportunity and provide us with biochemical 
endpoints with which to evaluate candidate therapeutics in model systems. Further, biofluid 
proteomic methods engineered for biomarker discovery (reviewed elsewhere; e.g., [2,16–
26]) can be repurposed to develop theragnostic assays with which to prescribe, optimize 
administration, and assess drug efficacy. In the next five years we expect proteomics to play 
a more decisive role in the development and translation of impactful TBI therapeutics.
Modeled TBI proteomics as a pharmaceutical test-bench
Ineffective translation of drug candidates has propelled the need to augment therapeutics 
research in TBI [14,27–30]. The latest large-scale proteomic technologies promise 
fundamental change in how we select and study drugs for TBI, providing the capacity to 
assess tens-of-thousands post-translational endpoints for TBI relevance and drug actions in a 
high-throughput, non-targeted analysis. TBI model systems serve as requisite test platforms 
with which to assess proteomic change, allowing control over cross-species populations, 
injury modality and severity, and intervention variables that require more rigorous pre-
clinical evaluation ahead of costly clinical trials. Take the recent work of Mehan et al. in 
which they applied proteomics to assess subject age as a confounding factor in TBI outcome 
[31]. Proteomic results revealed that TBI increased the transmission of serum albumin 
proteins (SAPs) into the injured juvenile and young adult brain; however, the SAP response 
was absent in a geriatric cohort (21 month old rats). Thus, in addition to a more porous 
blood-brain barrier (BBB), the aged brain is now found to be defective in SAP-mediated 
transport after TBI. SAPs transport important neuroprotective factors (steroids, fatty acids, 
etc.); thus, their deficiency represents an important aged-associated vulnerability to TBI that 
would benefit from a targeted intervention to improve outcome specifically for older TBI 
patients.
In vitro models are also called for in deciphering inter- and intra-cellular aspects of the 
proteomic response to TBI. For example, Loov et al. employed a co-culture scratch model to 
assess the neuroproteomic response following a neuronal transection injury in the presence 
of supporting astrocytes, but not infiltrating inflammatory cells or commingled vascular 
pathology [32]. Applying non-targeted proteomics to this culture system, they identified 
novel factors secreted from deformed cells into the media, which otherwise would have been 
indistinguishable from intracellular proteomic change. They found that 28% of the secreted 
proteins were actin-interactors, such as the astrocyte-associated proteins ezrin and moesin. 
Live cell imaging revealed that these proteins are critical to astrocytic engulfment of dying 
cells, as later validated in an in vivo TBI model. Modulating those factors may prove 
beneficial in enhance debris clean-up after TBI. In all, TBI model systems provide the 
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workbench with which to test the effect of population and injury variables on the 
pathobiology of TBI and inform on biochemical targets for selective intervention.
Multifactor designs are necessary to interpret the TBI proteome
Future proteomics research needs to capitalize on multi-factorial study designs in order to 
better account for anatomical, cellular and temporal dimensionality. Interpreting these 
datasets will be biased by where and when changes take place. For example, Mehan et al. 
report that CRMP2 levels increased in abundance within neocortex but decreased within 
hippocampus at three days post-TBI [31]. CRMP2 is responsible for establishing neurite 
polarity during synaptogenesis; thus, there is a region specific propensity and/or timing of 
synaptic degeneration and remodeling that must be considered in evaluating systemic 
therapeutic interventions. Injury modality and severity must also be considered per their 
effect on the biochemical and neurobiological response to TBI. We recently reported 
differential pro-survival responses between traumatic and ischemic-only modalities of brain 
injury, despite a proportional burden of cell death [33]. Chaperone (Hsp70 and bound 
14-3-3’s) and antioxidant (Prdx) protein levels increased in cortical tissue two days 
following ischemic injury, while levels decreased in the same region following focal TBI. 
The proteomic response for proteins associated with cell survival, metabolic and synaptic 
dysregulation, were further correlated with the magnitude of injury. All together, the 
multifaceted influence of injury and subject variables must be accounted for in order to 
address how interventions will respond when challenged by the heterogeneity of clinical 
TBI.
TBI proteomics must also address complexity from sub-cellular translocation, post-
translational modification and alternative isoform translation. Resolving the TBI proteome 
into soluble and membrane-insoluble fractions [34], we were able to deduce protein shifts 
from membrane-bound to matrix pools. For example, we discerned membrane-dissociation 
of vinculin after TBI, an integrin complexing protein relevant to synaptic destabilization and 
process retraction. We further found that translocated proteins were also post-translationally 
modified. Vinculin, for instance, exhibited increased phosphorylation at serine 721 [35]. 
Such investigations are now possible with careful analysis of individual peptide measures, in 
contrast with traditional peptide-to-protein roll-up analysis. Peptide-level assessment also 
divulges isoform-specific changes after TBI. For example, a unique peptide from a 
developmental isoform of neurofascin (NF125) was selectively increased in spared 
neocortex after TBI. In contrast, peptides common to mature NF155 and NF186 isoforms 
showed no change at the same time point. Immunoblot results affirmed that only the NF125 
isoform was significantly upregulated. NF125 is transiently expressed during development 
to secure oligodendrocyte-axon contact [36]. Peptide-level data revealed that NF125 is also 
repurposed following TBI, perhaps to affirm axon-myelin contact. We have identified a 
multitude of uncommon protein isoforms within the TBI-responsive proteome, portending 
an important, yet underappreciated role for alternative translation in TBI pathobiology that 
can now be assessed with TBI proteomics.
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Time as critical factor in TBI proteomic studies
The temporal evolution of TBI pathobiology may be well recognized by researchers 
(conceptualized in Figure 1); yet, few large-scale proteomic studies have incorporated time 
in their design, hampering our understanding of the data. A recent study by Wu et al. helps 
illustrate how profiling the proteomic response to TBI resolves ambiguity in interpreting 
results [37]. With one of the most comprehensive TBI proteome datasets published to date, 
Wu et al. employed sophisticated informatic methods to identify calcineurin B1 (CANB1) as 
a central node in the down-regulation of the actin-tubulin structural network within injured 
hippocampus. However, as with most TBI proteomic studies, their data were generated at a 
single 4-day post-injury time point. Thus, the results lacked the temporal detail needed to 
interpret the observed CANB1 modulation, which could be associated with the tail-end of 
acute neuroprotection from calcium-initiated degeneration or the beginning of a post-acute 
impairment of neuronal outgrowth. After considering data from Bales et al., they were able 
to determine that their results aligned with an almost immediate CANB1 reduction (by two 
hours) in protecting against calcium dysregulation [38]. Interestingly, CANB1 was then 
upregulated two weeks after TBI suggesting a post-acute neurotrophic function. Further 
support for TBI proteomic profiling can be found in a proteomic study by Evans et al. where 
they identified an inverse temporal relationship between the loss of mature MBP and 
initiation of myelin-associated glycoprotein (MAG) over three month period after injury 
[39]. We further observed that MAG undergoes transient dephosphorylated at Y611 and 
Y620 between one and two weeks following TBI (2.8-fold relative to naïve control; 
p=8.3E-7, n=6 per group), two key L-MAG signaling motifs for initiating myelination [40]. 
Yet, signaling mechanisms can easily be missed with a static or under-sampled study design. 
While we have just scratch the surface, such data divulge the temporal complexity 
surrounding molecular events underlying pathophysiological processes such as myelination 
dynamics, and further reflects the complexity to which therapeutics must be applied.
Temporal proteomics captures the sequence of TBI molecular mechanisms
TBI proteomic profiling allows proper characterization of evolving biochemical processes. 
While temporal proteomics represents a resource intensive, big-data challenge, we 
appreciate, reflecting on Figure 1, how a static view of TBI dynamics will omit critical 
information that ultimately prevents us from effectively understanding what occurs. 
Consider, for example, how protein-protein network analysis (informatics now commonly 
used in proteomics) results are easily skewed when using data from one time point to 
interpret biochemical processes that unfold across time. Too often we miss much of the story 
simply by under-sampling the dynamic events of TBI. Addressing this limitation, we 
recently assessed 23674 biologically reproduced peptide measures from 2243 proteins (n=6/
time point) between 2, 4, 7 and 14 days following moderate controlled cortical impact in the 
rat. Evaluating these data, we observed substantial evolution within the TBI proteome (from 
spared neocortical tissue, outside the glial scar [34]). At two days after injury we observed 
6209 TBI-responsive peptides; yet, by day 14, over half (52%) of the TBI-responsive 
peptides were novel. All told, 65% of measured proteins (1472) responded at some point 
within two weeks following TBI, significantly expanding our understanding of just how 
complex the proteomic response to injury happens to be.
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Yet, these data provide us with novel insight into the sequential processes occurring after 
injury. For instance, we uncovered a post-TBI molecular sequence that echoed a mechanism 
employed in inhibitory network formation during neurodevelopment [41]. We observed 
(Figure 2A): (1) ubiquitination of neuroligin 2 (NL-2) at lysine K749 on day two and (2) 
NL-2 dephosphorylation at serine S714 by day four. NL2 is a selective inhibitory trans-
synaptic anchor that also mediates axon guidance during synaptogenesis. These 
modifications correlated with NL-2 dissociation from cell soma by day two and then from 
distal synapses by day four (Figure 2B). (3) Synaptic membrane localization of the chloride 
symporter KCC2 declined significantly starting at day four (Figure 2A), causing 
GABAergic transmission to become excitatory (depolarizing) as in development [42]. KCC2 
remained dislocated through day seven in our study, consistent with an earlier report of 
reduced KCC2 levels in hippocampus at one week post-TBI [43], while NL-2 S714 
phosphorylation recovered by this time. (4) By day seven, there was also a reduction in 
membrane-associated polymerized gephyrin (Figure 2A) attributable to synapse 
destabilization. The revealed molecular sequence (Figure 2C) tracks with the molecular 
mechanism for inhibitory network formation and likely is repurposed after TBI for 
dematuration and remodeling of the inhibitory network. While our present study is far from 
exhaustive, it illustrates the future potential of large-scale proteomics in elucidating post-
TBI temporal processes that may then be targeted for therapeutic intervention.
TBI proteomics as a framework to develop and optimize interventions
Proteomic data provides a roadmap with which to target and evaluate candidate TBI 
therapeutics. For instance, the molecular sequence discussed above defines multiple 
intervention prospects (Figure 3). Transient KCC2 destabilization between days 4 and 14 
suggests the use of compounds such as 2,5-dimethoxy-4-iodoamphetamine (DOI) that 
promote KCC2 expression and stabilization of the inhibitory network [44–46]. In modeled 
spinal cord injury, DOI treatment restored KCC2 levels and recovered chloride homeostasis 
resulting in a functional reduction in spasticity. In tandem with targeting KCC2, drugs like 
dihydromyricetin (DHM) [47] may also assist in stabilizing the inhibitory network after 
injury by maintaining gephyrin polymerization [48,49], which holds together the post-
synaptic specialization [50–52]. Thus, we may look to molecular sequences revealed from 
temporal proteomics as guides for when and what interventions may be effective after TBI.
Recently Wang et al. published a study that illustrates translation of proteomic findings into 
a pre-clinical intervention with demonstrated functional efficacy [53]. Their proteomics 
study examined the molecular mechanisms underlying stem cell therapy in TBI [53]. They 
indentified that an unexpected smooth muscle-associated isoform of actin, SMA, was 
responsive to stem cell therapy after TBI. Both in vivo and in vitro models revealed that 
injury induced alpha-SMA, an isoform not normally found in the brain, as part of the 
mechanism regulating stress fiber formation, which in-turn inhibits neurite regeneration. 
They deduced that stem cell-released GDNF blocked TBI-induced RhoA signaling and 
subsequent alpha-SMA production, which enhanced neurite outgrowth and improved 
functional recovery. They later affirmed that they could pharmaceutically block RhoA 
induced alpha-SMA expression to effectively enhance neurite outgrowth after modeled TBI.
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TBI proteomics can also inform on as-yet unknown actions of pharmaceutics already under 
evaluation. Strides in this direction have already appeared within the stroke research 
community. Campos-Martorell et al. reported on a non-targeted proteomic study to 
investigate the mechanism by which simvastatin provides neuroprotection following rat 
embolic brain injury [54]. Their results show that oxidative stress pathways were attenuated 
by simvastatin, helping to preserve BBB integrity and minimize inflammation. Similarly, 
Zgavc et al. investigated the effect of hypothermia as a treatment in an endothelin-1 rat 
model of cerebral ischemia [55]. Proteomics revealed a positive effect on cellular assembly 
and organizational processes in the cortical penumbra. Specifically, BAIAP2L1 and A1AT 
were found to be novel mediators of hypothermic neuroprotection. The former is a brain 
specific 14-3-3 suppressor of p53-mediated apoptosis, while the latter inhibits neutrophil 
elastase to reduce vasogenic edema and BBB disruption. Proteomics is also conducive to 
testing candidate TBI drugs across species. Mass spectrometric analysis, unlikely 
immunological-based assays, can be easily ported from rodent to larger mammals for 
targeted and non-targeted assessments of inter-species pharmaceutical efficacy prior to the 
move into humans.
TBI proteomics in theragnostic biofluid assay development
Objective biofluid measures are sought to assist in identifying for whom and when to 
administer a given drug and assess biochemical efficacy. Existing biofluid proteomic 
methods and practices used for TBI biomarker discovery, validation and optimization (see 
Shen et al. for a recent update [56]) can be repurposed in devising theragnostic assays. 
Biofluid assays, when performed under carefully controlled conditions particularly with 
regard to clinical sampling parameters [57,58], promise a minimally invasive means to 
detect and monitor ongoing pathobiology for therapeutic management and prognosticating 
outcome [59–63]. Yet, to our knowledge, biofluid proteomic has yet to be used to develop 
TBI theragnostic assays. Again, looking to the stroke literature, we find an example from 
Campos-Martorell et al. [54]. After identifying that simvastatin helped preserve BBB 
integrity and minimize inflammation by attenuating oxidative stress, they then employed 
biofluid proteomics and resolved a correlation between HSP75 levels in plasma and 
simvastatin administration relative to placebo. Interventions for TBI may similarly induce 
biofluid changes that correlate with TBI biochemistry. Supporting this possibility, Boutte et 
al. recently demonstrated CSF measures track protein changes within injured neocortex CSF 
[64]. After modeled penetrating brain injury, syntaxin, tyrosine hydroxylase, UCH-L1, 
protein phosphatase 2C and cullin-1 proteins all increased proportionally in brain 
parenchyma and CSF, with a modest deviation in their temporal presentation.
Theragnostic assays are likely to employ a panel of biofluid measures, given the innate 
complexity of the biochemical response to TBI. Panel assays are espoused for their robust 
tolerance of inter-subject variability, yet to be effective in a theragnostic application, the 
selected measures should optimally correlate with the targeted pharmacology. Crawford et 
al. recently proposed employing protein-protein network analysis for panel assay 
development, whereby measures are selected based on their inter-relation through a common 
biochemical process [65]. In a similar fashion, network analysis could be adopted to develop 
a therapy-responsive biofluid assay. Another important finding in their study, Crawford et 
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al. observed a cluster of plasma proteins that varied in their temporal presentation in 
response to the severity of injury. A cohort of measures were present in blood one day 
following mild TBI but did not appear until three months after severe TBI, suggesting that a 
common biochemical process, perhaps linked with recovery, was delayed in onset with more 
severe TBI. Intervention windows are expected similarly to shift in time, particularly across 
the heterogeneous human TBI population, providing rationale for theragnostics. Siman et al. 
observed considerable inter-subject TBI variability in human CSF with their 11-protein 
assay [66,67]. The set of neuronal-derived CSF measures, developed with pre-clinical TBI 
proteomics, proved highly selective for TBI patients when assessed against normal pressure 
hydrocephalus and aortic surgical patients owed to its correlation with modeled neuronal 
injury. Yet, more work may prove valuable in linking these measures with specific 
biochemical processes that may be relevant to neuroprotective mechanisms. In this way, 
their bench-to-bedside proteomics approach may prove further beneficial in evaluating 
candidate drugs. Yet, theragnostic assays also need to correlate intervention with positive 
outcomes. Trajectory analysis as first demonstrated by Berger et al. offers a promising 
means with which to evaluate panel assay data against clinical outcome [68]. In their study, 
they showed that high-risk and low-risk trajectories were characterized by specific blood 
protein trajectories (S100B, NSE, MBP) in predicting better and worse outcomes, 
respectively. Drug-responsive TBI proteomic measures may similarly undergo trajectory 
model building to correlate intervention with positive outcomes.
Expert commentary and five-year view
The neurotrauma community recognizes a need to re-think how interventions are developed 
and translated effectively into the clinic. Current proteomic technology provides us with a 
novel, broad-scope window into the complex molecular processes underlying TBI, and 
stands to enable our ability to assess the influence of population- and injury-associated 
variables underlying the heterogeneity of clinical TBI. Thus, TBI proteomics will 
fundamentally change how we devise, test and translate TBI therapeutics over the next five 
years, as already begun in stroke. To achieve such impacts, proteomic study design and 
informatic approaches need significant attention. We are just now at the point where 
resources and technology allow for the temporal assessment of the large-scale proteomic 
response to TBI, yet the developing tools to resolve protein trajectory-maps and decipher 
patterns remains a fertile area of research. Methods will be devised to better track isoform-
selective dynamics and the range of post-translational signaling events that govern TBI-
altered biochemistry and function. Much as our society moves to address big-data 
challenges, we will gain the capacity to address the intricate nature of the TBI proteome and 
use that knowledge to advance development of TBI therapeutics to improve TBI patient 
care.
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Key Issues
• Despite growing public recognition and increased research attention, advances 
in TBI therapeutics have failed to materialize.
• Large-scale proteomics offers a forward-leap in our capacity to study the 
molecular impact of candidate drugs, both positive and negative, and how their 
action can be tailored across the injury and population factors that give rise to 
the heterogeneity of clinical TBI.
• Temporal characteristics of the neuroproteomic response to TBI are critical to 
understanding the sequential nature of the molecular processes governing 
secondary insults, recovery, and regeneration.
• Accounting for the breadth of translational and post-translational proteomic 
responses to TBI represents a monumental big-data challenge, requiring 
improved molecular characterization and informatic technologies.
• Objective biofluids measures of ongoing biochemical change are needed to 
assist translation of novel therapeutics. Theragnostic assays are needed for 
subject selection and as objective outcome measures in future clinical trials.
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Figure 1. TBI pathobiology comprises a series of biochemical and physiological events that 
initiate and evolve in an individualized fashion
The response to TBI is dynamic and individualize based on a host of population- and injury-
associated variables; yet, too often proteomic studies invoke static endpoint analysis. We 
must strive toward temporal analysis of the TBI proteome to effectively resolve the 
underlying processes of TBI and the extent to which they vary with key study factors.
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Figure 2. Decoding the temporal proteomic response to TBI: uncovered initiation cascade in 
remodeling the inhibitory synaptic network
Future applications of proteomics to TBI must consider the temporal dimensionality of the 
molecular response to TBI. For example, A. the initiation of inhibitory synaptic remodeling 
involves a series of post-translational events: (1) transient NL-2 ubiquitin signaling on K749 
by day two; (2) transient NL-2 dephosphorylation on S714 by day four; (3) dissociation of 
KCC2 symporters from the membrane between days four and 14; (4) depolymerization of 
membrane-tethered gephyrin by day seven through 14. Mean±SE, n=6 per time point. B. 
NL-2 immunofluorescence depicting loss of somatic NL-2 staining (centered at dashed 
circles) at day two coinciding with K749 ubiquitin signaling, followed by synaptic NL-2 
loss (red puncta) coinciding with S714 dephosphorylation at day four. NL-2 staining then 
recovers between seven and 14 days after TBI in time with recovery of S714 
phosphorylation. Representative images of layer 4 somatosensory cortex; bar = 10 μm. C. 
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Trajectory of molecular events in initiating inhibitory synaptic remodeling after TBI. CCI: 
controlled cortical impact; KCC2: potassium-chloride co-transporter 2; NL-2: neuroligin-2.
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Figure 3. TBI proteomics guides novel intervention opportunities in a systems biology approach
Proteomics provides us with an efficient means to investigate the diverse biochemistry 
underlying TBI pathobiology. As a broad-scope endpoint measure, proteomics is conducive 
to discovery analysis when integrated with targeted anatomical, physiological and functional 
assessments as affirmatory evidence. Proteomics can inform, for example, on the molecular 
sequence underlying critical period inhibitory network remodeling within the first few 
weeks following injury. Pharmaceutics may then be selected based on the proteomic results. 
For example, DOI and DHM may be efficacious in maintaining the inhibitory synaptic 
network by mitigating TBI-induced declines in KCC2 symporters and polymerized 
gephyrin, respectively, when administered appropriately within the defined critical window.
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